MDGL - Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on October 1, 2026 and October 14, 2026 to a total of 26 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

Oct 15, 2026 12:05 PM • globenewswire.com

Critical Review: Aurinia Pharmaceuticals (NASDAQ:AUPH) versus Madrigal Pharmaceuticals (NASDAQ:MDGL)

Aurinia Pharmaceuticals (NASDAQ: AUPH - Get Free Report) and Madrigal Pharmaceuticals (NASDAQ: MDGL - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, risk and institutional ownership. Profitability This table compares Aurinia Pharmaceuticals and Madrigal

Oct 11, 2026 10:15 PM • defenseworld.net

Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants

Secondary analysis of the Phase 3 MAESTRO-NASH trial demonstrated Rezdiffra improved histology and MRI-PDFF across common genetic variants associated with MASH progression CONSHOHOCKEN, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced the publication of a pre-specified secondary analysis from the Phase 3 MAESTRO-NASH trial in the Journal of Hepatology evaluating whether common genetic risk variants associated with MASH altered patient response to Rezdiffra® (resmetirom).

Oct 06, 2026 04:00 AM • globenewswire.com

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on September 1, 2026 and September 14, 2026 to a total of 27 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

Sep 16, 2026 12:05 PM • globenewswire.com

VIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 1,800 Madrigal Pharmaceuticals, Inc. $MDGL

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 1,800 shares of the biopharmaceutical company's stock, valued at approximately $967,000. A number of other large investors

Sep 14, 2026 12:45 AM • defenseworld.net

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Sep 10, 2026 11:17 AM • seekingalpha.com

Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?

Madrigal's only commercial drug, Rezdiffra, continues to grow sales. Institutional investors hold more than 95% of the stock's float.

Sep 10, 2026 08:00 AM • fool.com

Madrigal Pharmaceuticals to Participate in the  2026 Cantor Global Healthcare Conference

CONSHOHOCKEN, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the 2026 Cantor Global Healthcare Conference on Thursday, Sept.

Sep 02, 2026 04:00 AM • globenewswire.com

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Rating of “Moderate Buy” by Analysts

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eighteen research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and fifteen have issued a buy rating on the

Aug 30, 2026 10:29 PM • defenseworld.net

Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off

MASH cirrhosis could significantly expand Rezdiffra's addressable market. Madrigal's developing pipeline could reduce its dependence on Rezdiffra.

Aug 25, 2026 08:00 AM • fool.com

Allworth Financial LP Buys New Position in Madrigal Pharmaceuticals, Inc. $MDGL

Allworth Financial LP bought a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) in the second quarter, according to the company in its most recent filing with the SEC. The fund bought 3,562 shares of the biopharmaceutical company's stock, valued at approximately $1,913,000. Several other hedge funds and other institutional investors

Aug 21, 2026 11:07 PM • defenseworld.net

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on August 15, 2026 to 13 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

Aug 20, 2026 12:05 PM • globenewswire.com

Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands

Madrigal Pharmaceuticals (NASDAQ: MDGL) said Rezdiffra continued to post strong commercial growth in the second quarter of 2026, while the company expanded its development pipeline around the MASH therapy and prepared for several potential clinical catalysts. Speaking at a Canaccord Genuity event, Chief Financial Officer Mardi Dier said the company reported $364 million in second-quarter revenue,

Aug 16, 2026 09:03 PM • defenseworld.net

Madrigal's Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands

Madrigal Pharmaceuticals NASDAQ: MDGL said Rezdiffra continued to post strong commercial growth in the second quarter of 2026, while the company expanded its development pipeline around the MASH therapy and prepared for several potential clinical catalysts.

Aug 15, 2026 01:02 AM • marketbeat.com

John Paulson's Top Q2 2026 Move: Exiting Agnico Eagle Mines Ltd at a -5.11% Portfolio Impact

Paulson and Co. reshapes portfolio with a major gold stock exit and a new tech positionJohn Paulson (Trades, Portfolio), President and Portfolio Manager of Paulso

Aug 14, 2026 05:01 PM • gurufocus.com

Madrigal Appoints John C. Reed, M.D.

CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed John C.

Aug 12, 2026 04:00 AM • globenewswire.com

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

Aug 11, 2026 10:17 AM • seekingalpha.com

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on August 1, 2026 to ten new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan.

Aug 06, 2026 12:05 PM • globenewswire.com

Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, Aug. 11, 2026 at 12:00 P.M. EDT.

Aug 06, 2026 04:00 AM • globenewswire.com

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, CoreWeave, eBay, Exxon Mobil, Intuit, Nebius Group, Palantir Technologies, SK hynix, and More

Wall Street wasted no time Monday, sending the Nasdaq surging past 25,900 while analysts took aim at some of the market's biggest names with fresh upgrades, downgrades, and new coverage that could reshape how investors approach the week ahead.

Aug 04, 2026 04:11 AM • 247wallst.com

Madrigal Pharmaceuticals (MDGL) PT Raised to $735 at UBS

$735.00 (was $452.12)

Ashwani Verma · UBS

Oct 14, 2026 06:49 AM • StreetInsider

Madrigal Pharmaceuticals resumed with a Buy at Goldman Sachs

$704.00 (was $513.02)

Goldman Sachs

Sep 24, 2026 04:46 AM • TheFly

Madrigal upgraded to Outperform from Peer Perform at Wolfe Research

$605.00 (was $482.00)

Wolfe Research

Aug 04, 2026 05:22 AM • TheFly

Madrigal Pharmaceuticals (MDGL) PT Lowered to $962 at BarclaysMember Login

$962.00 (was $493.11)

Barclays

Jul 31, 2026 06:12 AM • StreetInsider

Madrigal Pharmaceuticals price target raised to $587 from $578 at Canaccord

$587.00 (was $538.80)

Canaccord Genuity

Jul 29, 2026 07:18 AM • TheFly

Madrigal Pharmaceuticals initiated with an Overweight at Wells Fargo

$685.00 (was $544.51)

Wells Fargo

Jul 27, 2026 05:22 AM • TheFly

Madrigal Pharmaceuticals (MDGL) PT Lowered to $542 at BofA Securities

$542.00 (was $471.32)

Morgan Stanley

Jun 11, 2026 05:11 AM • StreetInsider

Madrigal Pharmaceuticals price target raised to $709 from $640 at Truist

$709.00 (was $513.30)

Truist Financial

May 13, 2026 09:38 AM • TheFly

Madrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISI

$649.00 (was $539.73)

Evercore ISI

May 07, 2026 07:56 AM • TheFly

Madrigal Pharmaceuticals price target lowered to $578 from $587 at Canaccord

$578.00 (was $539.73)

Canaccord Genuity

May 07, 2026 06:53 AM • TheFly

Madrigal Pharmaceuticals initiated with an Overweight at Barclays

$964.00 (was $500.39)

Barclays

Jan 27, 2026 04:26 PM • TheFly

Goldman Sachs Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)

$571.00 (was $493.90)

Andrea Tan · Goldman Sachs

Jan 14, 2026 12:45 AM • StreetInsider

Wolfe downgrades Madrigal Pharmaceuticals to Peer Perform on valuation

$579.00 (was $588.40)

Andy Chen · Wolfe Research

Jan 06, 2026 07:53 AM • TheFly

Madrigal Pharmaceuticals (MDGL) PT Raised to $900 as Piper Sandler Recommends Buy

$900.00 (was $588.81)

Yasmeen Rahimi · Piper Sandler

Dec 19, 2025 08:28 AM • StreetInsider

Madrigal Pharmaceuticals price target raised to $900 from $540 at Piper Sandler

$900.00 (was $544.41)

UBS

Dec 19, 2025 06:49 AM • TheFly

Madrigal price target raised to $620 from $568 at H.C. Wainwright

$620.00 (was $558.61)

H.C. Wainwright

Nov 21, 2025 11:15 AM • TheFly

Madrigal Pharmaceuticals price target raised to $650 from $600 at Oppenheimer

$650.00 (was $568.01)

Jay Olson · Oppenheimer

Nov 20, 2025 07:41 AM • TheFly

Madrigal Pharmaceuticals price target raised to $640 from $580 at Truist

$640.00 (was $555.60)

Truist Financial

Nov 19, 2025 09:04 AM • TheFly

Madrigal Pharmaceuticals price target raised to $527 from $485 at Citizens JMP

$527.00 (was $444.64)

JMP Securities

Nov 05, 2025 05:47 AM • TheFly

Madrigal Pharmaceuticals price target raised to $540 from $400 at Piper Sandler

$540.00 (was $437.10)

Piper Sandler

Oct 15, 2025 06:38 AM • TheFly